Skip to main content
Erschienen in: BMC Infectious Diseases 1/2021

Open Access 01.12.2021 | Research

Factors affecting in-hospital mortality of non-tuberculous mycobacterial pulmonary disease

verfasst von: Goh Tanaka, Taisuke Jo, Hiroyuki Tamiya, Yukiyo Sakamoto, Wakae Hasegawa, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga, Takahide Nagase

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2021

Abstract

Background

The incidence and prevalence of non-tuberculous mycobacterial pulmonary disease (NTM-PD) are reportedly increasing in many parts of the world. However, there are few published data on NTM-PD-related death. Using data from a national inpatient database in Japan, we aimed in this study to identify the characteristics of patients with NTM-PD and clinical deterioration and to identify risk factors for in-hospital mortality.

Methods

We examined data from the Diagnosis Procedure Combination (DPC) database in Japan from July 2010 to March 2014. We extracted data for HIV-negative NTM-PD patients who required unscheduled hospitalization. We evaluated these patients’ characteristics and performed multivariable logistic regression analysis to identify risk factors for all-cause in-hospital mortality.

Results

A total of 16,192 patients (median age: 78 years; women: 61.2%) were identified. The median body mass index (BMI) was 17.5 kg/m2 (IQR 15.4–20.0). All cause In-hospital death occurred in 3166 patients (19.6%). The median BMI of the patients who had died was 16.0 kg/m2 (IQR 14.2–18.4). Multivariable analysis revealed that increased mortality was associated with male sex, lower BMI, lower activities of daily living scores on the Barthel index, hemoptysis, and comorbidities, including pulmonary infection other than NTM, interstitial lung disease, pneumothorax, and malignant disease.

Conclusions

We found associations between being underweight and having several comorbidities and increased in-hospital mortality in patients with NTM-PD. Preventing weight loss and management of comorbidities may have a crucial role in improving this disease’s prognosis.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BMI
Body mass index
COPD
Chronic obstructive pulmonary disease
DPC
Diagnosis Procedure Combination
DSM-5
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
ICD-10
International Statistical Classification of Diseases and Related Health Problems, 10th Revision
IQR
Interquartile range
MAC-PD
Mycobacterium avium complex pulmonary disease
NTM-PD
Non-tuberculous mycobacterial pulmonary disease

Background

Non-tuberculous mycobacterial pulmonary disease (NTM-PD) usually develops in middle-aged and older individuals, and is generally intractable and slowly progressive. The incidence and prevalence of NTM-PD are reportedly increasing in many parts of the world [17]. Increasing numbers of NTM-PD-related deaths among HIV-uninfected patients has also been reported in Japan [2] and the USA [8]. NTM-PD related deaths are expected to be a significant health problem in countries in which the population is aging.
Several population-based studies have identified the risk factors of male sex, older age, and some comorbidities for NTM-PD-related deaths [811]. Clinical conditions such as low body mass index (BMI) have also been shown to be associated with poor long-term prognosis of NTM-PD in some hospital-based studies [12, 13]; however, these studies had small patient cohorts. With regard to the significance of clinical deterioration of patients with NTM-PD, little information is available, particularly on in-hospital deaths. Evaluating risk factors for in-hospital mortality is crucial to improving the prognosis in patients with NTM-PD.
In this study, we used data from a nationwide database in Japan to investigate the characteristics and comorbidities of patients with NTM-PD who required unscheduled hospitalization and examined factors associated with in-hospital mortality in these patients.

Methods

Data source

We examined data from the Diagnosis Procedure Combination (DPC) database in Japan from July 2010 to March 2014. The database includes administrative claims data and discharge abstract data from more than 1200 hospitals, which covered 50% of the total bed capacity of acute care hospitals during the survey period. Primary diagnoses and comorbidities are recorded using International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) codes, accompanied by text data in Japanese. The database also contains the following information: age, sex, body height and weight, smoking status, grade of activity of daily living expressed as Barthel index score on admission, discharge status, therapeutic procedures, and medication use during hospitalization. This study was approved by the Institutional Review Board of The University of Tokyo and was performed in accordance with the Declaration of Helsinki. The requirement for informed consent was waived because of the anonymous nature of the data.

Patient selection and data

We retrospectively extracted data for patients with ICD-10 code: A310 (pulmonary mycobacterial infection) and A319 (Mycobacterial infection, unspecified). We did not include patients who were diagnosed with NTM extra-pulmonary disease (ICD-10 code, A311 and A318) during the study period. We included only the last hospitalization of patients who required unscheduled hospitalization more than once during the study period. We excluded patients < 18 years of age and those with HIV infection (ICD-10 code, B20–B24). We identified comorbidities using ICD-10 codes, as shown in Table 1. Because it is difficult to distinguish between primary bronchiectasis and bronchiectasis secondary to NTM-PD [14], we did not include the comorbidity of bronchiectasis in our study.
Table 1
ICD-10 codes used to identify comorbidities
Comorbidity
ICD-10 codes
Pulmonary infection
J100, J110, J12–J18, J20–22, J85, J86, J690
Pulmonary aspergillosis
B44
COPD
J43, J440, J441, J449
Bronchial asthma
J45, J46
Interstitial lung disease
J841, J848, J849
Pneumothorax
J93
Congestive heart failure
I110, I500, I501, I509
Ischemic heart disease
I20–I25
Cerebrovascular disease
I60–I69
Renal disease
N00–08, N10–N19
Autoimmune disease
M05, M06, M08, M30–M35
Diabetes mellitus
E10–E14
Bone fracture
S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T02, T10, T12
Lung cancer
C33, C34
Hematological malignancy
C81–C85, C88, C90–C96
Other malignant disease
C00–C97
To evaluate weight loss, we categorized BMI in accordance with the levels of severity of anorexia nervosa in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [15].
We used either ICD-10 codes (R042, R048, and R049) or treatment with intravenous hemostatic agents (carbazochrome sodium sulfonate and/or tranexamic acid) as indicators of clinically significant hemoptysis or bloody sputum. We then excluded patients with diagnoses of hemorrhage from organs other than lungs (ICD-10 codes shown in Table 2) and those who had undergone endoscopic procedures for hemostasis of gastrointestinal tract bleeding. We considered that arterial embolization performed in patients with hemoptysis was bronchial artery embolization.
Table 2
ICD-10 codes used to identify hemorrhage from organs other than lung
 
ICD-10 codes
Hemorrhage from urinary system
N288, N300, N304, N309, N328, N368, N421, N421, N488, N501, E274
Hemorrhage associated with gynecological disease
N645, N830, N831, N838, N908, N921–N924, N930, N938, N939, N950, N988, O209, O441, O469, O679, O695, O720–O722, O730, O731
Hemorrhage associated with otolaryngological disease
E078, H603, H669, H738, H922, R040, R041
Intracerebral hemorrhage
I60–I62
Spinal cord hemorrhage
G951, G968
Ocular hemorrhage
H113, H168, H208, H210, H313, H350, H356, H357, H405, H431, H448, H470
Traumatic hemorrhage
S013, S051, S063, S066, S068, S098, S368, S378, T144, T794
Postoperative hemorrhage
T810, T811
In addition, we extracted data concerning oral and intravenous treatment with various drugs, including corticosteroids and anti-mycobacterial agents. We evaluated prescription of the following antibiotics: rifamycins, including rifampicin and rifabutin; ethambutol; isoniazid; macrolides, including clarithromycin and azithromycin; aminoglycosides, including streptomycin, kanamycin, and amikacin; fluoroquinolones, including levofloxacin, moxifloxacin and sitafloxacin; and imipenem/cilastatin. We then assessed the combination of rifamycin, ethambutol, and clarithromycin, which is the recommended first line therapy for Mycobacterium avium complex pulmonary disease (MAC-PD) in Japan [16]. We also evaluated prescription of erythromycin, which has an anti-inflammatory effect in patients with chronic airway diseases.

Statistical analysis

We used χ2 tests to compare baseline characteristics, treatments, and procedures during hospitalization between patients who died during hospitalization and those who survived. We performed multivariable logistic regression to identify risk factors for all-cause in-hospital mortality. We used multiple imputation by the chained equations technique to deal with missing data on BMI, smoking history, and Barthel index scores. We included all the variables analyzed in this study in the imputation model and created 20 imputed datasets. We fitted multivariable logistic regression analyses for in-hospital mortality with generalized estimating equations to account for within-hospital clustering [17]. We obtained one set of statistical results on each imputed dataset and integrated them using Rubin’s combination rules [18]. We set statistical significance at less than 0.05 for all analyses. We performed statistical analyses using Stata/MP version 14 (StataCorp, College Station, TX, USA).

Results

Patient characteristics

We identified 16,280 patients with NTM-PD who required unscheduled hospitalization during the study period. We then excluded 24 patients aged < 18 years and 64 patients with HIV infection from the study, leaving 16,192 patients who were eligible for further analysis.
These patients characteristics are shown in Table 3. The median age was 78 years (interquartile range [IQR] 71–84) and 61.2% were women. The overall median BMI was 17.5 kg/m2 (IQR 15.4–20.0), being 18.1 kg/m2 (IQR 15.9–20.6) for men and 17.2 kg/m2 (IQR 15.2–19.5) for women. The most common comorbidity was pulmonary infection other than NTM (50.8%). As for primary diagnosis during hospitalization, pulmonary diseases accounted for 68.3% (pulmonary infection 28.8%, NTM-PD 23.1%, and other pulmonary disease 16.4%). Malignant diseases and other non-pulmonary diseases accounted for 4.1 and 27.6%, respectively.
Table 3
Baseline characteristics of patients with NTM pulmonary disease who required unscheduled hospitalization
 
Total (%)
Death (%)
P-value
n = 16,192
n = 3166
Sex
    
< 0.001
 Male
6283
(38.8)
1543
(48.7)
 
 Female
9909
(61.2)
1623
(51.3)
 
Age, years
    
< 0.001
  < 70
3400
(21.0)
455
(14.4)
 
 70–79
5374
(33.2)
1035
(32.7)
 
  ≥ 80
7418
(45.8)
1676
(52.9)
 
BMI, kg/m2
    
< 0.001
  < 15.0
2858
(17.7)
910
(28.7)
 
 15.0–15.9
1627
(10.0)
371
(11.7)
 
 16.0–16.9
1714
(10.6)
297
(9.4)
 
 17.0–18.4
2533
(15.6)
365
(11.5)
 
 18.5–24.9
5036
(31.1)
568
(17.9)
 
  ≥ 25.0
476
(2.9)
44
(1.4)
 
 Missing data
1948
(12.0)
611
(19.3)
 
Activities of daily living, Barthel index
    
< 0.001
 100
5137
(31.7)
354
(11.2)
 
 75–95
1553
(9.6)
159
(5.0)
 
 50–70
1921
(11.9)
336
(10.6)
 
 25–45
1225
(7.6)
296
(9.3)
 
 0–20
3818
(23.6)
1426
(45.0)
 
 Missing data
2538
(15.7)
595
(18.8)
 
Smoking history
    
< 0.001
 No
11,373
(70.2)
2083
(65.8)
 
 Yes
3167
(19.6)
668
(21.1)
 
 Missing data
1652
(10.2)
415
(13.1)
 
Symptom
     
 Hemoptysis
2996
(18.5)
528
(16.7)
0.003
Comorbidity
 Pulmonary disease
     
  Pulmonary infection
8225
(50.8)
2024
(63.9)
< 0.001
  Pulmonary aspergillosis
874
(5.4)
261
(8.2)
< 0.001
  COPD
1527
(9.4)
362
(11.4)
< 0.001
  Bronchial asthma
1158
(7.2)
181
(5.7)
< 0.001
  Interstitial lung disease
1171
(7.2)
384
(12.1)
< 0.001
  Pneumothorax
730
(4.5)
183
(5.8)
< 0.001
 Non-pulmonary disease
 Congestive heart failure
2279
(14.1)
650
(20.5)
< 0.001
 Ischemic heart disease
1123
(6.9)
184
(5.8)
0.006
 Cerebrovascular disease
1248
(7.7)
243
(7.7)
0.94
 Renal disease
853
(5.3)
218
(6.9)
< 0.001
 Autoimmune disease
1225
(7.6)
198
(6.3)
0.002
 Diabetes mellitus
2289
(14.1)
460
(14.5)
0.48
 Bone fracture
831
(5.1)
114
(3.6)
< 0.001
 Malignant disease
 Lung cancer
532
(3.3)
176
(5.6)
< 0.001
 Hematological malignancy
234
(1.4)
71
(2.2)
< 0.001
 Other malignant disease
1058
(6.5)
231
(7.3)
0.053

Treatments during hospitalization

Treatments during hospitalization are shown in Table 4; 44.6% of the 16,192 patients had not received any antibiotics with antimicrobial activity against NTM during the hospitalization, 3.2% had received monotherapy with erythromycin, and 15.2% had been treated with combination therapy including rifamycin, ethambutol and clarithromycin. Corticosteroids were prescribed for 20.9% of all patients.
Table 4
Treatment of study patients during hospitalization
 
Total (%)
Death (%)
P-value
n = 16,192
n = 3166
Medications prescribed during hospitalization
 No use of NTM drugsa
7215
(44.6)
1504
(47.5)
< 0.001
 Erythromycin only
526
(3.2)
61
(1.9)
< 0.001
 RIF, EMB, CLR
1676
(10.4)
232
(7.3)
< 0.001
 RIF, EMB, CLR, +FQ and/or AG
778
(4.8)
188
(5.9)
0.001
 Corticosteroidsb
3383
(20.9)
1069
(33.8)
< 0.001
Treatment procedure
 Bronchial artery embolization
250
(1.5)
22
(0.7)
< 0.001
 Mechanical ventilation
1518
(9.4)
957
(30.2)
< 0.001
aNTM drugs include the followings: rifampicin and rifabutin; ethambutol; isoniazid; macrolides, including clarithromycin and azithromycin; aminoglycosides, including streptomycin, kanamycin and amikacin; fluoroquinolones, including levofloxacin, moxifloxacin and sitafloxacin; and imipenem/cilastatin
bCorticosteroids include those administered both orally and intravenously
Abbreviations: AG aminoglycoside, CLR clarithromycin, EMB ethambutol, FQ fluoroquinolone, NTM non-tuberculous mycobacterial pulmonary disease, RIF rifampicin

All-cause in-hospital mortality

Overall, 3166 patients (19.6%) died during their unscheduled hospitalizations (Table 3). The median age of these patients was 80 years (IQR 74–85). The median BMI of all patients who died in hospital was 16.0 kg/m2 (IQR 14.2–18.4), comprising 16.6 kg/m2 (IQR 14.8–19.1) for men and 15.4 kg/m2 (IQR 13.7–17.6) for women. The median length of hospital stay was 18 days (IQR 10–34) in all patients and 21 days (IQR 8–44) in patients who died during hospitalization. Two-thirds of the patients who required mechanical ventilation died during the hospitalization (Table 4).
Table 5 shows the results of the multivariable logistic regression analysis for all-cause in-hospital mortality. Higher in-hospital mortality was associated with male sex, lower BMI, lower Barthel index score, hemoptysis, and comorbidities, including pulmonary infection other than NTM, pulmonary aspergillosis, interstitial lung disease, pneumothorax, congestive heart failure, renal disease, and malignant disease.
Table 5
Results of multivariable logistic regression analysis with multiple imputation for all-cause in-hospital mortality in patients with NTM pulmonary disease who required unscheduled hospitalization
 
OR
95% CI
P-value
Sex
 Male
1.89
(1.70–2.10)
< 0.001
Age, years
  < 70
reference
  
 70–79
1.12
(0.98–1.29)
0.11
  ≥ 80
1.04
(0.90–1.20)
0.56
BMI, kg/m2
  < 15.0
3.15
(2.74–3.62)
< 0.001
 15.0–15.9
2.15
(1.81–2.54)
< 0.001
 16.0–16.9
1.57
(1.31–1.87)
< 0.001
 17.0–18.4
1.31
(1.13–1.52)
< 0.001
 18.5–24.9
reference
  
  ≥ 25.0
0.83
(0.58–1.18)
0.30
Activities of daily living, Barthel index
 100
 reference
  
 75–95
1.45
(1.19–1.78)
< 0.001
 50–70
2.58
(2.18–3.06)
< 0.001
 25–45
3.74
(3.07–4.55)
< 0.001
 0–20
7.72
(6.68–8.92)
< 0.001
Smoking history
 Yes
0.89
(0.78–1.01)
0.077
Symptom
 Hemoptysis
1.21
(1.07–1.37)
0.002
Comorbidity
 Pulmonary disease
   
  Pulmonary infection
1.70
(1.54–1.87)
< 0.001
  Pulmonary aspergillosis
1.65
(1.39–1.96)
< 0.001
  COPD
0.96
(0.83–1.12)
0.63
  Bronchial asthma
0.81
(0.68–0.98)
0.027
  Interstitial lung disease
2.77
(2.37–3.24)
< 0.001
  Pneumothorax
1.40
(1.14–1.73)
0.001
 Non-pulmonary disease
 Congestive heart failure
1.62
(1.43–1.83)
< 0.001
 Ischemic heart disease
0.79
(0.66–0.95)
0.011
 Cerebrovascular disease
0.75
(0.63–0.88)
0.001
 Renal disease
1.46
(1.21–1.76)
< 0.001
 Autoimmune disease
0.85
(0.72–1.01)
0.072
 Diabetes mellitus
1.03
(0.90–1.18)
0.65
 Bone fracture
0.49
(0.39–0.61)
< 0.001
 Malignant disease
2.07
(1.79–2.39)
< 0.001

Discussion

In this study, we analyzed in-hospital mortality using data of more than 16,000 patients with NTM-PD drawn from a nationwide database in Japan. Pulmonary diseases accounted for 68.3% of primary diagnoses during these patients’ hospitalizations. The results of multivariable logistic regression analysis showed that male sex, lower BMI, lower Barthel index score, and hemoptysis were associated with higher in-hospital mortality. Several comorbidities were also associated with higher mortality.
Several previous population-based studies have evaluated risk factors for NTM-related deaths. These studies identified older age [8, 9, 11, 19] and male sex [911, 19] as potential risk factors for NTM-related deaths. Several comorbid diseases were also shown to be possible risk factors, including chronic obstructive pulmonary disease (COPD) [8, 11], lung cancer [10, 11, 19], bronchial asthma [10], pneumonia [10], and interstitial lung disease [11]. Bloody sputum was also associated with mortality in one single center study [20].
In the present study, we found that most of the participants (50.8%) had comorbid pulmonary infections in addition to NTM. Furthermore, pulmonary infection was significantly associated with in-hospital mortality, whereas, COPD and bronchial asthma were not. It remains unknown why COPD and bronchial asthma were not associated with higher in-hospital mortality. One possibility is that some of the patients hospitalized for exacerbations of COPD or bronchial asthma had better treatment responses.
Almost 90% of NTM-PD in Japan is reportedly MAC-PD [3]. In the present study, 15.2% of the patients received combination therapy including rifampicin, ethambutol, and clarithromycin, which is a standard regimen for MAC-PD, whereas 44.6% did not receive any antibiotics that target NTM. It seems likely that a relatively large proportion of patients in our study required unscheduled hospitalization for management of comorbid diseases or conditions.
In a previous study of 178 patients with NTM-PD from Oregon, USA, regular use of immunosuppressive medication was a risk factor for death [19]. In our study, about one third of patients who received corticosteroids after admission died during hospitalization. It is possible that most of the patients who were treated with corticosteroids had severe comorbidities on admission. Further studies are needed to elucidate the association between regular use of corticosteroids and prognosis of NTM-PD.
This study included BMI data in the multivariable analysis for mortality; to the best of our knowledge, no published studies have examined BMI prior to death in patients with NTM-PD. However, several studies have reported an association between weight loss and development of NTM-PD [12, 13, 2123]. In this study, patients with NTM-PD who required unscheduled hospitalization had remarkably low BMIs, the median being 17.5 kg/m2. Furthermore, lower BMI was strongly associated with higher in-hospital mortality. Our findings are in line with those of other hospital-based studies assessing long-term prognosis of MAC-PD patients in Japan, which have repeatedly shown that a BMI of less than 18.5 kg/m2 is associated with higher mortality [12, 13]. It is possible that most of the patients who died during their hospitalizations had cachexia, which is recognized as a complex metabolic syndrome [24].
Development of more effective anti-mycobacterial drugs may be crucial to preventing progression of NTM-PD. However, such drugs may not completely prevent progression of NTM-PD because some patients are likely to have polyclonal and mixed NTM infections acquired from the environment, as well as reinfection with NTM after treatment [25, 26]. Taken together, exploring host factors (such as the mechanisms by which severe weight loss affects susceptibility to, and progression of, NTM-PD) may be important in improving the prognosis of this disease. In fact, two previous studies have reported a possible role for inappropriately secreted adipokines in the pathogenesis of NTM-PD [27, 28]; however, their results were inconsistent and thus require further investigation.
Several limitations must be acknowledged. First, mild cases of NTM-PD without respiratory complications may have not been recorded by the attending physician; this would have resulted in low sensitivity for the diagnosis of mild cases of NTM-PD. NTM-PD is more likely to be diagnosed when it is has resulted in moderate to severe respiratory symptoms. Second, we may have underestimated the proportion of patients who were receiving combination therapy for MAC-PD because anti-mycobacterial drugs prescribed in the outpatient settings are usually withdrawn on admission in more severe cases. This would have prevented us from accurately evaluating the association between antibacterial therapies for NTM-PD and in-hospital mortality.

Conclusions

In the present study of data drawn from a nationwide inpatient database in Japan, we identified multiple factors associated with in-hospital mortality of NTM-PD. In particular, we found associations between pulmonary infection other than NTM and lower BMI and higher in-hospital mortality. Controlling for severe weight loss and comorbidities may play a key role in improving the prognosis of this disease.

Acknowledgements

Not applicable.

Declarations

Conduct of the study was approved by the Institutional Review Board of The University of Tokyo, which waived the requirement for informed consent owing to the anonymity of the data. This study was performed in accordance with the Declaration of Helsinki.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
16.
Zurück zum Zitat Japanese Society of Tuberculosis, Japanese Society of Respiratory Diseases. Opinions on chemotherapy of non-tuberculous acid-fast bacterial infection of the lung. Kekkaku. 2012;87:83–6 (in Japanese). Japanese Society of Tuberculosis, Japanese Society of Respiratory Diseases. Opinions on chemotherapy of non-tuberculous acid-fast bacterial infection of the lung. Kekkaku. 2012;87:83–6 (in Japanese).
21.
Zurück zum Zitat Song JH, Kim BS, Kwak N, Han KD, Yim JJ. Impact of body mass index on development of nontuberculous mycobacterial pulmonary disease. Eur Respir J. 2021;57(2):2000454. PMID: 32817261. Song JH, Kim BS, Kwak N, Han KD, Yim JJ. Impact of body mass index on development of nontuberculous mycobacterial pulmonary disease. Eur Respir J. 2021;57(2):2000454. PMID: 32817261.
Metadaten
Titel
Factors affecting in-hospital mortality of non-tuberculous mycobacterial pulmonary disease
verfasst von
Goh Tanaka
Taisuke Jo
Hiroyuki Tamiya
Yukiyo Sakamoto
Wakae Hasegawa
Hiroki Matsui
Kiyohide Fushimi
Hideo Yasunaga
Takahide Nagase
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2021
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06395-y

Weitere Artikel der Ausgabe 1/2021

BMC Infectious Diseases 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.